Cipla

Cipla, a Pharmaceutical Preparation Manufacturing company headquartered in India, reported its Scope 1 emissions for 2026 as approximately 38,426,000 kg CO2e and Scope 2 emissions as approximately 85,906,000 kg CO2e. For 2025, Scope 1 emissions were about 38,283,000 kg CO2e and Scope 2 emissions were approximately 129,087,000 kg CO2e. In 2024, the company recorded Scope 1 emissions of around 37,398,000 kg CO2e and Scope 2 emissions of approximately 207,238,000 kg CO2e. There is currently no Scope 3 emissions data available.

Cipla has several climate commitments, including aiming for carbon neutrality for its India manufacturing operations by December 2025 for both Scope 1 and Scope 2 emissions. This includes efforts to achieve near-zero Scope 1 and Scope 2 emissions by the middle of this decade. Furthermore, Cipla has set a target to reduce its absolute Scope 1 emissions by 30% from 2020 levels by 2030, and its Scope 2 emissions by 25% from 2020 levels by 2030. Another target indicates an 80% reduction in absolute Scope 1 (energy based) and Scope 2 emissions by 2025, against a 2019 baseline. The company plans to achieve these reductions through improved energy efficiency, increased use of renewable energy sources (electricity and biofuels), and alternative fuel sources like biomass.